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Signaling involving dopaminergic neurons in the brain is
important for determining the saliency of sensory input,
the urgency of sensory import, the actual value of an
experience as compared to its expected value, and the
process of converting motivation to action. Drugs that
are antagonists for the dopamine D2 receptor subtype
are clinically effective in treating schizophrenia and a
variety of other mental conditions. These drugs have a
substantial effect on the levels and sub-cellular distribu-
tion of dopamine and its major metabolite DOPAC.
Currently, there is no quantitative analysis of how these
various changes can be accomplished. The goal of this
work is to explain how the changes in dopamine and
DOPAC levels and subcellular location elicited by the
prototypical antipsychotic drug haloperidol occur.
A computational model of a dopaminergic striatal var-
icosity was used. In the model, dopamine can be located
in cytosol, vesicles, extracellular compartment, and a
DOPAC-synthesis-secretory compartment. DOPAC can
be located in cytosol, extracellular, and DOPAC-synth-
esis-secretory compartment. The model has two distinct
sites for dopamine and DOPAC synthesis. The cytosolic
site synthesizes dopamine for use in the signaling pool
and metabolizes a portion of dopamine that is transi-
ently located in cytosol. The DOPAC-synthesis-secretory
complex site is hypothesized to be located on the
plasma membrane and to be dedicated to the synthesis
of DOPAC to be secreted into the extracellular com-
partment. The model also has enzymes involved in
dopamine and DOPAC synthesis, transporters that
move dopamine between compartments, and exocytosis.
Haloperidol induces a small increase in extracellular
dopamine, a somewhat larger increase in extracellular
DOPAC, a larger increase in tissue DOPAC, a large
increase in rate of dopamine synthesis, and no change
in level of dopamine. The increase in extracellular dopa-
mine was simulated by increasing rate of secretion of
dopamine into extracellular space by exocytosis. An
increase in synthesis of signaling dopamine was required
to maintain the elevated levels of extracellular dopa-
mine. The increase in extracellular DOPAC was simu-
lated by increasing rate of dopamine synthesis in the
DOPAC-synthesis-secretory compartment. With only
these manipulations, the model failed to match experi-
mental data in terms of increase in total tissue DOPAC
and increase in the rate of dopamine synthesis. These
discrepancies were resolved by increasing the passive
diffusion of dopamine from vesicles to cytosol and
further increasing the rate of dopamine synthesis for the
signaling pool. Literature data indicate that haloperidol
does accumulate in and partially alkalinize amine neuro-
transmitter storage vesicles, which would increase pas-
sive diffusion of dopamine from the vesicles.
I conclude that the increases in extracellular dopamine
and DOPAC are likely mediated by antagonism of dopa-
mine D2 receptors but that the large increase in tissue
DOPAC and much of the increase in dopamine synth-
esis result from physico-chemical properties of haloperi-
dol rather than block of dopamine D2 receptors.
Furthermore, the results suggest dopaminergic varicos-
ities possess a mechanism for monitoring amount of
stored dopamine and modulating dopamine synthesis to
maintain constant stores.
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